Proposal of Platelet Anti-aggregation in Transplant Renal Artery Stenosis

Introduction Kidney transplant (KT) offers the best renal replacement therapy (RRT), not without being exempt from medical-surgical complications, highlighting those that impact graft function with elevated serum creatinine compounds, such as transplant renal artery stenosis (TRAS), and this study, in turn, has presented some gaps in knowledge, such as anti-aggregation therapy, essentially after the interventionist handling activity. The objective of this document is to propose a platelet anti-aggregation scheme and show the behavior of a series of cases, with a review of the literature. Materials and methods This is a case report of patients with TRAS for five years and six months; patients with a clinical imaging diagnosis of TRAS were included, who were managed with intervention and follow-up. Results In the study, a prevalence of 1.35% (11 of 813) of confirmed cases treated with angioplasty was documented; of the 11 cases, one had restenosis, and another had a thrombotic event requiring reintervention. Antiplatelet therapy was used in 11 patients: one patient was diagnosed at examination, three on the day of angioplasty, and seven cases within seven days after angioplasty. The duration of maintenance with dual or single antiplatelet therapy has not been standardized; in our cases, dual therapy lasted 1-9 months, followed by single antiplatelet therapy. Conclusions The interventional treatment of TRAS is safe; however, there is variability, and antiplatelet therapy is not standardized. This antiplatelet therapy should be determined based on risk factors, stenosis characteristics, and comorbidities. Based on all of this, this study is proposed to standardize antiplatelet therapy.